 Lisa Forman
Concepts (321)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Transplantation | 29 | 2024 | 871 | 3.770 |
Why?
| | Cholangitis, Sclerosing | 9 | 2025 | 75 | 2.130 |
Why?
| | Human Rights | 11 | 2022 | 28 | 2.080 |
Why?
| | Hepatitis C | 8 | 2021 | 271 | 1.370 |
Why?
| | Graft Rejection | 6 | 2024 | 624 | 1.290 |
Why?
| | End Stage Liver Disease | 3 | 2024 | 82 | 1.190 |
Why?
| | Drugs, Essential | 2 | 2021 | 8 | 0.900 |
Why?
| | Graft Survival | 7 | 2024 | 535 | 0.880 |
Why?
| | Social Determinants of Health | 2 | 2024 | 267 | 0.820 |
Why?
| | Health Services Accessibility | 9 | 2024 | 986 | 0.790 |
Why?
| | Vaccines | 2 | 2022 | 406 | 0.670 |
Why?
| | Pandemics | 5 | 2022 | 1639 | 0.630 |
Why?
| | Cannabinoids | 1 | 2021 | 161 | 0.610 |
Why?
| | Hepatitis, Autoimmune | 1 | 2018 | 20 | 0.590 |
Why?
| | Thrombosis | 1 | 2021 | 371 | 0.550 |
Why?
| | Aspartate Aminotransferases | 1 | 2017 | 90 | 0.540 |
Why?
| | Living Donors | 7 | 2023 | 295 | 0.530 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2021 | 445 | 0.530 |
Why?
| | Alanine Transaminase | 1 | 2017 | 157 | 0.520 |
Why?
| | Hepatitis C, Chronic | 4 | 2015 | 164 | 0.510 |
Why?
| | Hodgkin Disease | 1 | 2017 | 138 | 0.480 |
Why?
| | Glucocorticoids | 2 | 2018 | 594 | 0.460 |
Why?
| | Hepacivirus | 4 | 2021 | 261 | 0.450 |
Why?
| | Gastroenterology | 2 | 2009 | 180 | 0.420 |
Why?
| | Global Health | 5 | 2022 | 386 | 0.410 |
Why?
| | Humans | 73 | 2025 | 137585 | 0.400 |
Why?
| | Waiting Lists | 4 | 2024 | 266 | 0.370 |
Why?
| | Liver Cirrhosis, Biliary | 2 | 2023 | 18 | 0.370 |
Why?
| | Pneumonia, Viral | 3 | 2020 | 373 | 0.350 |
Why?
| | Coronavirus Infections | 3 | 2020 | 364 | 0.350 |
Why?
| | Recurrence | 7 | 2023 | 1060 | 0.330 |
Why?
| | Liver | 3 | 2017 | 1943 | 0.330 |
Why?
| | Pruritus | 3 | 2025 | 63 | 0.330 |
Why?
| | Travel | 2 | 2022 | 130 | 0.320 |
Why?
| | Delivery of Health Care | 1 | 2016 | 951 | 0.310 |
Why?
| | Antiviral Agents | 4 | 2015 | 744 | 0.310 |
Why?
| | Liver Diseases | 3 | 2019 | 315 | 0.310 |
Why?
| | Severity of Illness Index | 8 | 2025 | 2828 | 0.300 |
Why?
| | Treatment Outcome | 14 | 2024 | 10811 | 0.300 |
Why?
| | Healthcare Disparities | 2 | 2024 | 654 | 0.280 |
Why?
| | Liver Failure | 3 | 2008 | 94 | 0.270 |
Why?
| | Canada | 4 | 2023 | 418 | 0.270 |
Why?
| | Anemia, Hemolytic, Congenital Nonspherocytic | 4 | 1997 | 5 | 0.270 |
Why?
| | Liver Cirrhosis | 3 | 2015 | 316 | 0.250 |
Why?
| | Fibrosis | 1 | 2008 | 552 | 0.240 |
Why?
| | Middle Aged | 25 | 2025 | 33479 | 0.230 |
Why?
| | Health Care Rationing | 2 | 2004 | 59 | 0.220 |
Why?
| | Foreign-Body Migration | 1 | 2004 | 34 | 0.220 |
Why?
| | Ribavirin | 2 | 2005 | 91 | 0.220 |
Why?
| | Purpura, Thrombocytopenic, Idiopathic | 1 | 2004 | 15 | 0.210 |
Why?
| | Cholestasis | 2 | 2025 | 235 | 0.210 |
Why?
| | Portasystemic Shunt, Transjugular Intrahepatic | 1 | 2004 | 44 | 0.210 |
Why?
| | Anemia, Hemolytic | 4 | 1998 | 20 | 0.210 |
Why?
| | Public Health Surveillance | 2 | 2020 | 82 | 0.210 |
Why?
| | Interferon-alpha | 2 | 2005 | 198 | 0.210 |
Why?
| | Tissue Donors | 4 | 2013 | 425 | 0.210 |
Why?
| | Heart Atria | 1 | 2004 | 137 | 0.210 |
Why?
| | Resource Allocation | 1 | 2004 | 52 | 0.210 |
Why?
| | Patient Selection | 4 | 2013 | 696 | 0.200 |
Why?
| | Adult | 25 | 2025 | 37929 | 0.200 |
Why?
| | Insurance | 1 | 2023 | 14 | 0.200 |
Why?
| | Berberine | 1 | 2022 | 6 | 0.200 |
Why?
| | Registries | 4 | 2025 | 2035 | 0.200 |
Why?
| | Aged | 16 | 2025 | 23961 | 0.190 |
Why?
| | Cannabidiol | 1 | 2024 | 119 | 0.190 |
Why?
| | Male | 30 | 2025 | 67762 | 0.190 |
Why?
| | Liver Cirrhosis, Alcoholic | 1 | 2021 | 17 | 0.180 |
Why?
| | Acquired Immunodeficiency Syndrome | 1 | 2023 | 230 | 0.180 |
Why?
| | Cholangiocarcinoma | 1 | 2022 | 104 | 0.180 |
Why?
| | Dronabinol | 1 | 2024 | 226 | 0.180 |
Why?
| | Retrospective Studies | 14 | 2025 | 15657 | 0.180 |
Why?
| | Bile Duct Neoplasms | 1 | 2022 | 124 | 0.180 |
Why?
| | Female | 29 | 2025 | 73304 | 0.180 |
Why?
| | International Law | 1 | 2020 | 1 | 0.170 |
Why?
| | Investments | 1 | 2019 | 7 | 0.160 |
Why?
| | Technology | 1 | 2020 | 96 | 0.160 |
Why?
| | Violence | 1 | 2023 | 266 | 0.160 |
Why?
| | Thiazoles | 1 | 2000 | 123 | 0.160 |
Why?
| | Transplant Recipients | 1 | 2021 | 184 | 0.160 |
Why?
| | Inflammatory Bowel Diseases | 1 | 2024 | 351 | 0.150 |
Why?
| | Public Policy | 1 | 2019 | 85 | 0.150 |
Why?
| | Thiazolidinediones | 1 | 2000 | 137 | 0.150 |
Why?
| | International Cooperation | 1 | 2019 | 198 | 0.150 |
Why?
| | Erythrocyte Aging | 4 | 1998 | 17 | 0.150 |
Why?
| | Commerce | 1 | 2019 | 82 | 0.150 |
Why?
| | Primary Health Care | 1 | 2009 | 1738 | 0.150 |
Why?
| | Parkinson Disease | 1 | 2024 | 493 | 0.140 |
Why?
| | Glucose-6-Phosphate Isomerase | 1 | 1997 | 3 | 0.140 |
Why?
| | Withholding Treatment | 1 | 2018 | 76 | 0.140 |
Why?
| | Ursodeoxycholic Acid | 3 | 2023 | 21 | 0.140 |
Why?
| | Mobile Applications | 1 | 2020 | 183 | 0.140 |
Why?
| | Postoperative Complications | 3 | 2011 | 2654 | 0.140 |
Why?
| | Pharmaceutical Preparations | 1 | 2019 | 179 | 0.140 |
Why?
| | Biopsy | 3 | 2017 | 1129 | 0.140 |
Why?
| | Time Factors | 6 | 2018 | 6828 | 0.140 |
Why?
| | United States | 7 | 2025 | 14841 | 0.130 |
Why?
| | Models, Theoretical | 1 | 2001 | 578 | 0.130 |
Why?
| | Transients and Migrants | 1 | 2017 | 24 | 0.130 |
Why?
| | Risk Factors | 7 | 2024 | 10388 | 0.130 |
Why?
| | Aortic Valve Insufficiency | 1 | 2015 | 47 | 0.120 |
Why?
| | Intellectual Property | 3 | 2021 | 10 | 0.120 |
Why?
| | HIV Infections | 2 | 2023 | 2836 | 0.110 |
Why?
| | Hepatic Artery | 2 | 2004 | 62 | 0.110 |
Why?
| | Glucosephosphate Dehydrogenase | 3 | 1991 | 60 | 0.110 |
Why?
| | Alkaline Phosphatase | 3 | 2023 | 148 | 0.110 |
Why?
| | Transcatheter Aortic Valve Replacement | 1 | 2015 | 130 | 0.110 |
Why?
| | Cholangitis | 1 | 2013 | 21 | 0.100 |
Why?
| | Diagnosis, Differential | 1 | 2017 | 1483 | 0.100 |
Why?
| | Immunohistochemistry | 1 | 2017 | 1738 | 0.100 |
Why?
| | Transplantation | 1 | 2013 | 34 | 0.100 |
Why?
| | Aortic Valve Stenosis | 1 | 2015 | 229 | 0.100 |
Why?
| | Hepatitis C Antibodies | 1 | 2012 | 11 | 0.100 |
Why?
| | Non-alcoholic Fatty Liver Disease | 1 | 2015 | 279 | 0.100 |
Why?
| | DEAD-box RNA Helicases | 1 | 2013 | 76 | 0.090 |
Why?
| | Universities | 1 | 2014 | 433 | 0.090 |
Why?
| | Erythrocytes | 5 | 1990 | 700 | 0.090 |
Why?
| | Bile Acids and Salts | 2 | 2023 | 200 | 0.090 |
Why?
| | Interleukins | 1 | 2013 | 250 | 0.090 |
Why?
| | Research | 1 | 2014 | 451 | 0.090 |
Why?
| | Hypoglycemic Agents | 1 | 2000 | 1291 | 0.090 |
Why?
| | Carcinoma, Hepatocellular | 2 | 2004 | 362 | 0.080 |
Why?
| | Biomarkers, Tumor | 1 | 2017 | 1276 | 0.080 |
Why?
| | Glutathione Synthase | 1 | 1990 | 3 | 0.080 |
Why?
| | Mutation | 3 | 1997 | 3958 | 0.080 |
Why?
| | Peptide Synthases | 1 | 1990 | 5 | 0.080 |
Why?
| | Hepatitis B, Chronic | 1 | 2010 | 23 | 0.080 |
Why?
| | Hepatitis B Vaccines | 1 | 2010 | 45 | 0.080 |
Why?
| | World Health Organization | 2 | 2020 | 123 | 0.080 |
Why?
| | Duodenostomy | 1 | 2009 | 5 | 0.080 |
Why?
| | Gallbladder | 1 | 2009 | 19 | 0.080 |
Why?
| | Anastomosis, Roux-en-Y | 1 | 2009 | 28 | 0.080 |
Why?
| | Immunoglobulins | 1 | 2010 | 171 | 0.080 |
Why?
| | Adenine Nucleotides | 1 | 1989 | 23 | 0.080 |
Why?
| | Proportional Hazards Models | 4 | 2015 | 1266 | 0.080 |
Why?
| | Disease Progression | 3 | 2015 | 2757 | 0.070 |
Why?
| | Hepatopulmonary Syndrome | 1 | 2008 | 25 | 0.070 |
Why?
| | Glutathione Transferase | 1 | 1988 | 106 | 0.070 |
Why?
| | Genotype | 4 | 2015 | 1916 | 0.070 |
Why?
| | Glutathione | 1 | 1990 | 356 | 0.070 |
Why?
| | Physicians, Family | 1 | 2009 | 201 | 0.070 |
Why?
| | Coronary Disease | 2 | 2001 | 385 | 0.070 |
Why?
| | Postoperative Care | 1 | 2009 | 261 | 0.070 |
Why?
| | Medicine | 1 | 2009 | 121 | 0.070 |
Why?
| | Liver Neoplasms | 2 | 2004 | 786 | 0.070 |
Why?
| | Hepatectomy | 1 | 2009 | 251 | 0.070 |
Why?
| | Prevalence | 3 | 2025 | 2734 | 0.070 |
Why?
| | Betacoronavirus | 2 | 2020 | 270 | 0.070 |
Why?
| | Continuity of Patient Care | 1 | 2009 | 284 | 0.070 |
Why?
| | Survival Analysis | 3 | 2004 | 1325 | 0.060 |
Why?
| | Donor Selection | 1 | 2006 | 77 | 0.060 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2013 | 2189 | 0.060 |
Why?
| | Duodenal Diseases | 1 | 2004 | 8 | 0.060 |
Why?
| | Intestinal Fistula | 1 | 2004 | 17 | 0.060 |
Why?
| | Vascular Fistula | 1 | 2004 | 23 | 0.060 |
Why?
| | Metabolic Syndrome | 1 | 2008 | 354 | 0.060 |
Why?
| | Aneurysm, False | 1 | 2004 | 48 | 0.060 |
Why?
| | Quality of Life | 2 | 2023 | 2892 | 0.050 |
Why?
| | Calcineurin Inhibitors | 1 | 2003 | 72 | 0.050 |
Why?
| | Delayed Diagnosis | 1 | 2024 | 91 | 0.050 |
Why?
| | Cholagogues and Choleretics | 1 | 2023 | 8 | 0.050 |
Why?
| | Radiography, Interventional | 1 | 2004 | 116 | 0.050 |
Why?
| | Caribbean Region | 1 | 2023 | 28 | 0.050 |
Why?
| | Chemoembolization, Therapeutic | 1 | 2004 | 91 | 0.050 |
Why?
| | Anthropology, Cultural | 1 | 2023 | 22 | 0.050 |
Why?
| | Tissue and Organ Procurement | 2 | 2004 | 321 | 0.050 |
Why?
| | Acetates | 1 | 2023 | 99 | 0.050 |
Why?
| | Hepatocytes | 1 | 2003 | 220 | 0.050 |
Why?
| | Effect Modifier, Epidemiologic | 1 | 2002 | 12 | 0.050 |
Why?
| | Bile Ducts, Intrahepatic | 1 | 2022 | 78 | 0.050 |
Why?
| | Uncertainty | 1 | 2023 | 128 | 0.050 |
Why?
| | Vancomycin | 1 | 2023 | 84 | 0.050 |
Why?
| | Sirolimus | 1 | 2003 | 276 | 0.050 |
Why?
| | Vaccination | 1 | 2010 | 1381 | 0.040 |
Why?
| | Echocardiography | 1 | 2004 | 642 | 0.040 |
Why?
| | Survival Rate | 2 | 2004 | 1972 | 0.040 |
Why?
| | Reoperation | 1 | 2003 | 573 | 0.040 |
Why?
| | Sensitivity and Specificity | 2 | 2004 | 1946 | 0.040 |
Why?
| | Health Priorities | 1 | 2021 | 44 | 0.040 |
Why?
| | Privacy | 1 | 2020 | 42 | 0.040 |
Why?
| | Multivariate Analysis | 2 | 2015 | 1509 | 0.040 |
Why?
| | Verapamil | 1 | 2000 | 41 | 0.040 |
Why?
| | Stents | 1 | 2004 | 527 | 0.040 |
Why?
| | Pravastatin | 1 | 2000 | 41 | 0.040 |
Why?
| | Chenodeoxycholic Acid | 1 | 2019 | 16 | 0.040 |
Why?
| | Socioeconomic Factors | 1 | 2024 | 1289 | 0.040 |
Why?
| | Diabetes Mellitus | 1 | 2008 | 1040 | 0.040 |
Why?
| | Biotin | 2 | 1990 | 28 | 0.040 |
Why?
| | Mexico | 1 | 2019 | 225 | 0.040 |
Why?
| | Double-Blind Method | 1 | 2024 | 1993 | 0.040 |
Why?
| | Coronary Artery Bypass | 1 | 2001 | 234 | 0.040 |
Why?
| | Costs and Cost Analysis | 1 | 2019 | 213 | 0.040 |
Why?
| | Surveys and Questionnaires | 2 | 2009 | 5778 | 0.040 |
Why?
| | Drug Interactions | 1 | 2000 | 410 | 0.040 |
Why?
| | Anemia, Hemolytic, Congenital | 2 | 1988 | 3 | 0.040 |
Why?
| | Erythrocyte Membrane | 1 | 1998 | 55 | 0.040 |
Why?
| | Phosphatidylserines | 1 | 1998 | 91 | 0.030 |
Why?
| | Monitoring, Physiologic | 1 | 2000 | 275 | 0.030 |
Why?
| | Pilot Projects | 1 | 2023 | 1710 | 0.030 |
Why?
| | Cohort Studies | 2 | 2012 | 5742 | 0.030 |
Why?
| | United Nations | 1 | 2017 | 8 | 0.030 |
Why?
| | RNA, Viral | 2 | 2015 | 656 | 0.030 |
Why?
| | Organizational Objectives | 1 | 2017 | 73 | 0.030 |
Why?
| | Combined Modality Therapy | 1 | 2000 | 1236 | 0.030 |
Why?
| | North America | 1 | 2017 | 313 | 0.030 |
Why?
| | Ischemia | 1 | 2000 | 409 | 0.030 |
Why?
| | Prognosis | 2 | 2004 | 4030 | 0.030 |
Why?
| | Cardiovascular Diseases | 1 | 2008 | 2111 | 0.030 |
Why?
| | Pyruvate Kinase | 3 | 1998 | 29 | 0.030 |
Why?
| | Refugees | 1 | 2017 | 75 | 0.030 |
Why?
| | Rabbits | 3 | 1998 | 794 | 0.030 |
Why?
| | Public Health | 1 | 2020 | 588 | 0.030 |
Why?
| | Guidelines as Topic | 1 | 2017 | 275 | 0.030 |
Why?
| | Chronic Disease | 1 | 2001 | 1793 | 0.030 |
Why?
| | Thrombelastography | 1 | 2015 | 154 | 0.030 |
Why?
| | Organizational Case Studies | 1 | 2014 | 78 | 0.030 |
Why?
| | Financing, Organized | 1 | 2014 | 35 | 0.030 |
Why?
| | Femoral Artery | 1 | 2015 | 179 | 0.030 |
Why?
| | Chi-Square Distribution | 1 | 2015 | 530 | 0.030 |
Why?
| | Genes | 2 | 1991 | 230 | 0.030 |
Why?
| | DEAD Box Protein 58 | 1 | 2013 | 9 | 0.030 |
Why?
| | Viral Load | 1 | 2015 | 466 | 0.030 |
Why?
| | Pennsylvania | 1 | 2013 | 116 | 0.030 |
Why?
| | Phenylhydrazines | 2 | 1990 | 5 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2015 | 889 | 0.020 |
Why?
| | Anti-Bacterial Agents | 1 | 2023 | 1809 | 0.020 |
Why?
| | Developing Countries | 1 | 2014 | 307 | 0.020 |
Why?
| | Psychiatric Status Rating Scales | 1 | 1994 | 547 | 0.020 |
Why?
| | Infant, Newborn | 2 | 1997 | 6079 | 0.020 |
Why?
| | Follow-Up Studies | 2 | 2013 | 5131 | 0.020 |
Why?
| | Receptors, Immunologic | 1 | 2013 | 216 | 0.020 |
Why?
| | Depression | 1 | 2001 | 1397 | 0.020 |
Why?
| | Cooperative Behavior | 1 | 2014 | 451 | 0.020 |
Why?
| | Interferons | 1 | 2013 | 202 | 0.020 |
Why?
| | Kinetics | 2 | 1998 | 1670 | 0.020 |
Why?
| | Sex Distribution | 1 | 2011 | 375 | 0.020 |
Why?
| | Leadership | 1 | 2014 | 388 | 0.020 |
Why?
| | Oligonucleotides | 1 | 1991 | 148 | 0.020 |
Why?
| | NADP | 1 | 1989 | 49 | 0.020 |
Why?
| | Introns | 1 | 1991 | 258 | 0.020 |
Why?
| | Hepatitis B virus | 1 | 2010 | 40 | 0.020 |
Why?
| | Length of Stay | 2 | 2009 | 1215 | 0.020 |
Why?
| | Immunization, Passive | 1 | 2010 | 90 | 0.020 |
Why?
| | Child | 5 | 1997 | 21935 | 0.020 |
Why?
| | Cholangiography | 1 | 2009 | 17 | 0.020 |
Why?
| | Risk Assessment | 2 | 2013 | 3457 | 0.020 |
Why?
| | Risk | 1 | 2012 | 912 | 0.020 |
Why?
| | Molecular Sequence Data | 2 | 1991 | 2900 | 0.020 |
Why?
| | Monitoring, Intraoperative | 1 | 2009 | 56 | 0.020 |
Why?
| | Adenosine Kinase | 1 | 1989 | 3 | 0.020 |
Why?
| | Patient Acceptance of Health Care | 1 | 2015 | 806 | 0.020 |
Why?
| | AMP Deaminase | 1 | 1989 | 12 | 0.020 |
Why?
| | Erythroblasts | 1 | 1989 | 19 | 0.020 |
Why?
| | 5'-Nucleotidase | 1 | 1989 | 41 | 0.020 |
Why?
| | Anastomosis, Surgical | 1 | 2009 | 153 | 0.020 |
Why?
| | Antigen-Antibody Reactions | 1 | 1988 | 55 | 0.020 |
Why?
| | Pedigree | 1 | 1990 | 514 | 0.020 |
Why?
| | Secondary Prevention | 1 | 2010 | 233 | 0.020 |
Why?
| | Intracellular Fluid | 1 | 1988 | 27 | 0.020 |
Why?
| | Immune Sera | 1 | 1988 | 88 | 0.020 |
Why?
| | Enzyme Stability | 1 | 1988 | 70 | 0.020 |
Why?
| | Clinical Enzyme Tests | 1 | 1988 | 11 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 1991 | 1062 | 0.020 |
Why?
| | Hypertension, Portal | 1 | 2008 | 64 | 0.020 |
Why?
| | DNA, Viral | 1 | 2010 | 364 | 0.020 |
Why?
| | Medical Records | 1 | 2008 | 177 | 0.020 |
Why?
| | Administration, Oral | 1 | 2010 | 816 | 0.020 |
Why?
| | Antibody Formation | 1 | 1989 | 298 | 0.020 |
Why?
| | Base Sequence | 1 | 1991 | 2181 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2017 | 5472 | 0.020 |
Why?
| | Preoperative Care | 1 | 2008 | 362 | 0.020 |
Why?
| | Mental Disorders | 1 | 1994 | 1077 | 0.020 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2000 | 2531 | 0.010 |
Why?
| | Sex Factors | 1 | 2011 | 2071 | 0.010 |
Why?
| | Case-Control Studies | 1 | 2013 | 3556 | 0.010 |
Why?
| | Pregnancy | 1 | 1997 | 6763 | 0.010 |
Why?
| | Survival | 1 | 2004 | 38 | 0.010 |
Why?
| | Genetic Predisposition to Disease | 1 | 2013 | 2426 | 0.010 |
Why?
| | alpha-Fetoproteins | 1 | 2004 | 46 | 0.010 |
Why?
| | Glucosephosphate Dehydrogenase Deficiency | 2 | 1998 | 32 | 0.010 |
Why?
| | Microsomes, Liver | 1 | 2003 | 86 | 0.010 |
Why?
| | Comorbidity | 1 | 2008 | 1622 | 0.010 |
Why?
| | Probability | 1 | 2004 | 304 | 0.010 |
Why?
| | Colorado | 1 | 2013 | 4565 | 0.010 |
Why?
| | Transplantation, Homologous | 1 | 2004 | 416 | 0.010 |
Why?
| | Cyclosporine | 1 | 2003 | 268 | 0.010 |
Why?
| | Tacrolimus | 1 | 2003 | 199 | 0.010 |
Why?
| | Recombinant Proteins | 1 | 2005 | 1353 | 0.010 |
Why?
| | Adolescent | 4 | 2006 | 21513 | 0.010 |
Why?
| | Observation | 1 | 2001 | 50 | 0.010 |
Why?
| | Young Adult | 1 | 2017 | 13209 | 0.010 |
Why?
| | Neoplasm Staging | 1 | 2004 | 1389 | 0.010 |
Why?
| | Health Surveys | 1 | 2001 | 514 | 0.010 |
Why?
| | Immunosuppressive Agents | 1 | 2003 | 890 | 0.010 |
Why?
| | Spherocytosis, Hereditary | 1 | 1998 | 1 | 0.010 |
Why?
| | Hemoglobins, Abnormal | 1 | 1998 | 11 | 0.010 |
Why?
| | Biotinylation | 1 | 1998 | 32 | 0.010 |
Why?
| | Predictive Value of Tests | 1 | 2003 | 2031 | 0.010 |
Why?
| | Infant | 2 | 1988 | 9465 | 0.010 |
Why?
| | Child, Preschool | 2 | 1988 | 11074 | 0.010 |
Why?
| | Animals | 4 | 1998 | 36940 | 0.010 |
Why?
| | Prospective Studies | 1 | 2008 | 7604 | 0.010 |
Why?
| | Models, Biological | 1 | 2003 | 1783 | 0.010 |
Why?
| | Patient Readmission | 1 | 2001 | 697 | 0.010 |
Why?
| | History, 17th Century | 1 | 1994 | 16 | 0.010 |
Why?
| | History, 18th Century | 1 | 1994 | 19 | 0.010 |
Why?
| | Cell Survival | 1 | 1998 | 1120 | 0.010 |
Why?
| | History, Ancient | 1 | 1994 | 54 | 0.010 |
Why?
| | History, 19th Century | 1 | 1994 | 60 | 0.010 |
Why?
| | Europe | 1 | 1994 | 414 | 0.010 |
Why?
| | Longitudinal Studies | 1 | 2001 | 2844 | 0.010 |
Why?
| | History, 20th Century | 1 | 1994 | 325 | 0.010 |
Why?
| | Hexokinase | 1 | 1990 | 19 | 0.010 |
Why?
| | Oligonucleotide Probes | 1 | 1989 | 51 | 0.010 |
Why?
| | Sequence Homology, Nucleic Acid | 1 | 1989 | 155 | 0.010 |
Why?
| | Gene Amplification | 1 | 1989 | 104 | 0.000 |
Why?
| | Cell Separation | 1 | 1990 | 318 | 0.000 |
Why?
| | Binding Sites | 1 | 1989 | 1303 | 0.000 |
Why?
| | Amino Acid Sequence | 1 | 1989 | 2139 | 0.000 |
Why?
| | Genetic Variation | 1 | 1989 | 991 | 0.000 |
Why?
| | DNA | 1 | 1989 | 1459 | 0.000 |
Why?
| | Aged, 80 and over | 1 | 1988 | 7635 | 0.000 |
Why?
|
|
Forman's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|